TMEM175 modulator / AbbVie, Merck (MSD) - LARVOL DELTA

Caraway Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Businesswire) - "Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Thursday, September 23, 2021 at 2:55pm Eastern Time. The presentation will cover recent progress from Caraway’s lead program targeting modulation of the lysosomal cation channel, TRPML1, for GBA-Parkinson’s disease and other rare diseases, and highlight the recently established collaboration with AbbVie on Caraway’s second program targeting the lysosomal potassium channel, TMEM175, for Parkinson’s and other neurodegenerative diseases."

Licensing / partnership • CNS Disorders • Parkinson's Disease

Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders (Businesswire) - "Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to develop and commercialize Caraway’s small molecule therapeutics targeting TMEM175, a potassium ion channel critical to lysosomal function implicated in both Parkinson’s disease (PD) and other neurodegenerative disorders....Under the terms of the agreement, Caraway will receive an upfront cash payment of $17 million...AbbVie has an option to license the program and proceed into IND-enabling studies, clinical development, and commercialization."

Licensing / partnership • New molecule • CNS Disorders • Parkinson's Disease